摘要
目的:积极推进国家医保谈判药品的常态化落地,提升国家医保谈判药品的供应保障水平及透明化程度,促进药品回归临床价值.方法:依据2022年5月河北省卫生健康委员会组织制定下发的《河北省三级公立医疗机构用药(化学药品)目录遴选评价表(试行)》中的评价体系,针对拟遴选入院的61个国家医保谈判药品,从有效性、药学特性、安全性、经济性、其他属性5个维度进行综合评价.结果:47个国家医保谈判西药中,29个药品前3项评分≥50分;34个药品前4项评分≥60分;39个药品总分≥60分;24个药品前3项评分≥50分、前4项评分≥60分、总分≥70分;7个药品前3项评分＜50分、前4项评分＜60分、总分＜70分.14个国家医保谈判中药中,同时满足前3项评分≥50分、前4项评分≥60分、总分≥70分的药品数量与同时满足前3项评分＜50分、前4项评分＜60分、总分＜70分的药品数量均为6个.结论:本研究运用量化评价体系对国家医保谈判药品的有效性、药学特性、安全性、经济性等指标进行全方位评价,赋予量化分值,构建满足医疗机构需求的国家医保谈判药品综合评价数据库,通过综合分数来提取出"优"的国家医保谈判药品,过程快速、科学、公正、透明.
Abstract
OBJECTIVE:To actively promote the normalization of national medical insurance negotiation drugs,enhance the level of supply security and transparency of national medical insurance negotiation drugs,and promote the return of drugs to clinical value.METHODS:According to the evaluation system of Selection and Evaluation Form of Drug Use(Chemical Drugs)List in the Tertiary Public Medical Institutions in Hebei Province formulated and issued by the Health Commission of Hebei Province in May 2022,the effectiveness,pharmaceutical characteristics,safety,economy and other attributes of 61 national medical insurance negotiation drugs were comprehensively evaluated.RESULTS:Among the 47 Western medicines negotiated by the National Health Insurance,29 medicines had a score of ≥50 points in the first 3 items;34 medicines had a score of ≥60 points in the first 4 items;39 medicines had a total score of ≥ 60 points;24 medicines had a score of ≥ 50 points in the first 3 items,≥ 60 points in the first 4 items,and a total score of ≥70 points;and 7 medicines had a score of＜50 points in the first 3 items,＜60 points in the first 4 items,and a total score of＜70 points.Among the 14 Chinese medicines negotiated by the National Health Insurance,the number of medicines that had a score of ≥50 points in the first 3 items,≥60 points in the first 4 items and the total score ≥ 70 points and the number of medicines that had a score of＜50 points in the first 3 items,＜60 points in the first 4 items and the total score＜70 points were both 6.CONCLUSIONS:In this study,a quantitative evaluation system is used to comprehensively evaluate the effectiveness,pharmaceutical characteristics,safety,economy and other indicators of national medical insurance negotiation drugs,assign quantitative scores,establish the comprehensive evaluation database of national medical insurance negotiation drugs that meets the needs of medical institutions,and the"Excellent"national medical insurance negotiation drugs are extracted by comprehensive scores.The process is rapid,scientific,fair and transparent.
维普
万方数据